Report Description Table of Contents Industry Report and Statistics (Facts & Figures) The market for bacteriophage therapy in 2023 was worth USD 43.47 Million and is expected to be worth USD 64.61 Million by 2032, expanding at a 4.5% CAGR. In today's world, bacterial infections are becoming increasingly resistant to antibiotics. Therefore, Western medicine needs to explore alternative therapeutic options to combat such infections. While the development of new antibiotics is noticeably less common, bacteriophage therapies have emerged as a promising solution. These therapies can be used in conjunction with antibiotics to produce synergies and offer a different approach to antibacterial treatments. In phage therapy, viruses are employed to transfer genetic material into bacteria. This process enables the viruses to use the resources of their host to multiply. Phage therapy is used to treat or prevent bacterial infections in patients. Besides, bacteriophage therapy is essential in molecular biology and technological research because it broadens the potential field of drug discovery. Phage has many potential applications in veterinary medicine, agriculture, and human medicine. Several early-stage clinical trials are underway at the moment. BiomX, an Israeli company, recently shared the results of a Phase I a trial. The trial focused on patients with high levels of Klebsiella pneumoniae, a bacteria linked to inflammatory bowel disease and primary sclerosing cholangitis. The trial used phage targeting as a method. The business demonstrated that the phages were proliferating in situ and that there were higher-than-normal levels of phages in the feces samples from these patients. Antimicrobial resistance is a major challenge for the healthcare industry and a global health issue. The use of bacteriophages as treatments has recently gained popularity due to increased antibiotic resistance. In 2019, AMR bacterial infections caused over 1.2 million deaths. The rise in antibiotic resistant bacteria poses a significant risk to public health and is regarded as one of modern medicine's biggest problems. An alternate course of treatment for bacterial infections may be provided by phage therapy, which uses bacteriophages as antibacterial agents. Phages hold great promise in the fields of human medicine, dentistry, veterinary medicine, agriculture, and food safety. Market Drivers (The Phage Revolution? Key Drivers Propelling a New Era of Antibiotic Alternatives) Factors like the rising rate of infectious disease and the rising incidence of antibiotic resistance are stimulating the growth of the bacteriophage therapy market. One major factor boosting the growth of the bacteriophage therapy market is the growing rate of infectious diseases. Human health is significantly endangered by bacterial infectious illnesses. WHO reports that infectious diseases account for almost 25% of global fatalities and that 38% of human infections are bacteria. UTI is one of the most common infectious diseases globally. In 2019, 404.61 million UTI cases, 236,790 deaths, and 520,200 DALYs were reported worldwide, a 2.4-time increase in the death rate from 1990 to 2019. In medical settings, up to 9.4% of patients receive a diagnosis of UTIs related to their treatment. For instance, UTIs are linked to a 2.3% attributable mortality rate in hospitalized patients and an estimated $340 to $450 million in annual costs in the US. Antibiotic resistance is currently one of the most significant problems that public health is facing globally, accounting for at least 1.27 million deaths globally. The increased prescription and dispensing of antibiotic medications in underdeveloped nations contributes to the global growth in antimicrobial resistance. An estimated 700,000 to several million people die from it annually, and it still poses a serious risk to public health globally. In the US, antibiotic-resistant bacteria affect at least 2.8 million people, resulting in at least 35,000 deaths annualy and $55 billion in higher medical expenses and lost productivity. The World Health Organization (WHO) predicts that by 2050, antimicrobial resistance (AMR) might cause 350 million deaths. By then, a United Nations report estimates that 10 million people will have died annually. Thus, the rising incidence of antibiotic resistance will significantly boost the demand for bacteriophage therapy, leading to market growth. Restraints (Promising Treatment, Uncertain Future: Bacteriophage Therapy Market Faces Restraints) The complicated regulatory approval procedures can make it difficult to commercialize bacteriophage treatments. Getting these treatments onto the market requires navigating regulatory restrictions and proving safety and efficacy to regulatory bodies. The current limits of bacteriophage therapy are the lack of purity and stability in the solution, as well as the decrease in concentration between the site of delivery and the bacterial infection. Naturally occurring phage aggregation and microfiltration have been used to achieve phage purification. Production guidelines and legal frameworks must be established when phage products become more prevalent and readily available to maintain the same safety and accessibility as antimicrobial treatments. Opportunity (Beyond the Hype: Exploring Untapped Opportunities in Phage Therapy) As bacteriophage therapy shows promise, regulatory bodies are trying to set standards for its research and approval. Regulatory support is essential for bacteriophage-based products to be commercialized and widely used. The FDA of the United States accepted the INDs for the customized PhageBank therapy developed by Adaptive Phage Therapeutics in a groundbreaking move. The company is now conducting phase 1–3 studies for three PhageBank treatment pipelines. Thus, rising regulatory support will open up new growth opportunities in the future. A promising indicator for the expansion of the bacteriophage therapy industry is the rise in funding for research and development, clinical trials, and commercialization initiatives from the public and private sectors. Recently, 12 institutes worldwide received $2.5 million from the US National Institutes of Health to investigate phage therapy. Clinical investigations are also being conducted. One such experiment is a multi-center Phase 1b/2 study, which evaluates the microbiological activity of a single phage therapy dose in individuals with cystic fibrosis who have a persistent P. aeruginosa colony. The safety, tolerability, pharmacokinetics, and efficacy of a phage medicinal product for treating acute, uncomplicated UTIs caused by MDR E. coli were assessed in a phase 2/3 trial initiated by Locus in July 2022. Who Needs Phage Therapy? Segmenting the Market for Targeted Solutions The market for bacteriophage therapy is segmented on the basis of application, target bacteria, and region. By Application Food industry Human Medicine Veterinary Science Agriculture Others By Target Bacteria E. coli Staphylococcus aeruginosa Pseudomonas aeruginosa Streptococcus salmonella Others By Region (Phages Go Global: A Look at the Bacteriophage Therapy Market Across Regions) North America • USA • Canada Asia Pacific • China • India • Japan • South Korea • Australia • Rest of APAC Europe • France • UK • Germany • Spain • Italy • Rest of Europe Combating Foodborne Illnesses: Bacteriophages' Impact on the Food Industry On the basis of application, the Food Industry comprehensively dominated the market in 2023 with revenue share of 25%. Each year, foodborne illnesses with microbiological origins significantly impact the food processing sector and public health. Therefore, developing innovative strategies for reducing microbial contamination in foods requires public health and financial incentives. Because of their strong and incredibly targeted antibacterial activity, bacteriophages are among the various antimicrobial agents. The Centers for Disease Control & Prevention report that 48 million instances of food poisoning occur annually in the United States alone, resulting in 128,000 hospitalizations and 3,000 deaths. Bacteriophage Therapy for E. Coli: Addressing Major Pathogen Challenges On the basis of target bacteria, E. Coli comprehensively dominated the market in 2023 with a revenie share of 30%. One of the most prevalent pathogens in humans, Escherichia coli, can cause infections in various bodily organs, including enteritis, septicemia, newborn meningitis, and urinary tract infections. Uropathogenic E. Coli is the most prevalent pathogen that causes UTIs, and UTIs are the most common extra-intestinal E. Coli infection (UPEC). Exploring Bacteriophage Therapy: North America's Growing Role in Combatting Resistant Infections The North American market held a largest market position in 2023 with a revenue share of 40%. The use of bacteriophage therapy is growing in North America due to rising concerns about antibiotic resistance and the requirement for substitute treatments for bacterial disease. Scientists and medical professionals in North America are exploring bacteriophage therapy as a potential treatment for bacterial infections resistant to traditional antibiotics. The South Korean biotech business iNtRON Biotechnology has been contracted by the US Army to create bacteriophages to treat uropathogenic Escherichia coli (UPEC) infections. The US Army DEVCOM (US Army Combat Capabilities Development Command) International Technology Center Indo-Pacific and Solider Center chose the project through the Foreign Technology Assessment Support (FTAS) program. Leading the Charge: A Look at Key Players in Bacteriophage Therapy Phagomed Biopharma GmbH Eliava Biopreparations Ltd. Locus Biosciences Micreos BV Nextbiotics Phagelux InnoPhage Amrata Pharmaceuticals Inc. TechnoPhage Adaptive Phage Therapeutics Fixed-Phage Ltd. ContraFect Corporation Others Bacteriophage Therapy Market Report Coverage Report Attribute Details Forecast Period 2023 - 2032 Market size value in 2023 USD 43.47 Million Revenue Forecast in 2032 USD 64.61 Million Growth rate CAGR of approximately 4.5% Base year for estimation 2022 Historical data 2017 – 2021 Unit USD Billion, CAGR (2024 - 2032) Segmentation By Application, By Target Bacteria, By Route Of Administration By Application Food Industry, Human Medicine, Veterinary Science, Agriculture, Others By Target Bacteria E. coli, Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus, Salmonella, Others By Route of Administration Oral, Topical, Rectal, Intravenous By Region Asia Pacific, North America, Europe, LAMEA Country Scope U.S., Canada, France, Germany, U.K., China, Japan, India, South Korea, Mexico, Brazil, U.A.E. etc. Company Usability Profiles Phagomed Biopharma GmbH, Eliava Biopreparations Ltd., Locus Biosciences, Micreos BV, Nextbiotics, Phagelux, InnoPhage, Amrata Pharmaceuticals Inc., TechnoPhage, Adaptive Phage Therapeutics, Fixed-Phage Ltd., ContraFect Corporation, Others Pricing and purchase options Avail customized purchase options to meet your exact research needs. The Future of Phage Therapy: Highlighting Recent Developments In October 2023, The development of safe and effective bacteriophages to fight disease has advanced, and this effort has been boosted by £800,000. The Biotechnology & Biological Sciences Research Council project aims to advance phage production for veterinary disease prevention and marketability. It has been given to Dr. Anisha Thanki, who earlier in 2023 successfully produced a bacteriophage 'liquid' solution to prevent Salmonella in broiler chicks, & the Director of the Leicester Centre of Phage Research, Professor Martha Clokie. The latter will now be employed as a case study to explore methods for the safe and effective larger-scale production of this innovative drug in compliance with UK regulations. In January 2023, APT, a biotechnology company in its clinical stage, announced that the first patient in the PHAGE clinical trial had received a dose. The trial is testing bacteriophage therapy for Pseudomonas aeruginosa in adults with cystic fibrosis. The APT phage bank is the world's largest therapeutic phage initiative for bacterial infectious diseases. The experiment aims to determine whether bacteriophage or "phage," therapy is safe and effective in lowering the number of germs in participants' lungs. The Antibacterial Resistance Leadership Group (ARLG), comprising over 100 top professionals, is conducting an experiment to tackle the challenge of antibacterial resistance and improve patient care. In July 2023, An agreement was made between Armata Pharmaceuticals, Inc. and Innoviva Strategic Opportunities LLC for credit and security. Armata Pharmaceuticals is a biotechnology company specializing in pathogen-specific bacteriophage therapeutics for antibiotic-resistant and challenging-to-treat bacterial infections. Armata announced a change in leadership today as the credit agreement's gross proceeds, excluding transaction-related costs, total $25 million at closure. Frequently Asked Question About This Report . Table of Contents 1. EXECUTIVE SUMMARY 1.1. Market Attractiveness 1.2. Understanding the Target Customers 1.3. CXO perspective 1.4. Global Bacteriophage Therapy Market, Historical Market Size & Future Projections Analysis 1.5. Global Bacteriophage Therapy Market, By Application 1.6. Global Bacteriophage Therapy Market, By Target Bacteria 1.7. Global Bacteriophage Therapy Market, By Route of Administration 1.8. Global Bacteriophage Therapy Market, By Region 2. MARKET SHARE ANALYSIS 2.1. Top 10 Players with Revenue and Sales Volume 2.2. Market Share, 2024 3. SALES VOLUME (METRIC TONNES), BY REGION 3.1. Europe (UK, Germany, France, Netherlands, Italy, Spain, Belgium, Sweden, Denmark, Norway, Aland Islands, Rest of Europe) 3.2. Asia (China, Japan, South Korea, India, Indonesia, Rest of Asia) 3.3. Middle-East (Israel, Saudi Arabia, UAE, Qatar, Egypt, Kuwait, Bahrain, and Others) 4. INVESTMENT OPPORTUNITIES IN THE MARKET 4.1. On Going Market Developments 4.2. Merger & Acquisition Trends 4.3. Key Investment Opportunities 4.4. Most Potential Product Application Segments from Growth and Investment Perspective 5. MARKET INTRODUCTION 5.1. Definition 5.2. Scope of the Study 5.3. Market Structure 5.4. Macro Factor Indicator Analysis 5.5. Key findings 5.5.1. Top investment pockets 6. RESEARCH METHODOLOGY 6.1. Research Process 6.2. Primary Research 6.3. Secondary Research 6.4. Market Size Estimation 6.5. Forecast Model 7. MARKET DYNAMICS 7.1. Introduction 7.2. Drivers 7.3. Restraints 7.4. Opportunities 7.5. Challenges 7.6. Covid 19 Impact Analysis 8. GLOBAL BACTERIOPHAGE THERAPY MARKET ANALYSIS BY SEGMENT (REGION LEVEL ANALYSIS) 8.1. Overview 8.2. Global Bacteriophage Therapy Historical Market size ($MILLION), Sales Volume, (2022 – 2032) 8.3. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032) 8.4. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Application 8.4.1. Food industry 8.4.2. Human Medicine 8.4.3. Veterinary Science 8.4.4. Agriculture 8.4.5. Others 8.5. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Target Bacteria 8.5.1. E. coli 8.5.2. Staphylococcus aeruginosa 8.5.3. Pseudomonas aeruginosa 8.5.4. Streptococcus 8.5.5. Salmonella 8.5.6. Others 8.6. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Route of Administration 8.6.1. Oral 8.6.2. Topical 8.6.3. Rectal 8.6.4. Intravenous 8.7. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Geography 8.7.1. Asia 8.7.2. North America 8.7.3. Europe 8.7.4. Middle East 9. NORTH AMERICA BACTERIOPHAGE THERAPY MARKET ANALYSIS BY SEGMENT (REGION LEVEL ANALYSIS) 9.1. Overview 9.2. North America Bacteriophage Therapy Historical Market size ($MILLION), Sales Volume, (2022 – 2032) 9.3. North America Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032) 9.4. North America Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Application 9.4.1. Food industry 9.4.2. Human Medicine 9.4.3. Veterinary Science 9.4.4. Agriculture 9.4.5. Others 9.5. North America Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Target Bacteria 9.5.1. E. coli 9.5.2. Staphylococcus aeruginosa 9.5.3. Pseudomonas aeruginosa 9.5.4. Streptococcus 9.5.5. Salmonella 9.5.6. Others 9.6. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Route of Administration 9.6.1. Oral 9.6.2. Topical 9.6.3. Rectal 9.6.4. Intravenous 9.7. North America Pseudomonas aeruginosa Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Geography 9.7.1. USA 9.7.1.1. California 9.7.1.2. Texas 9.7.1.3. Florida 9.7.1.4. Pennsylvania 9.7.1.5. Illinois 9.7.1.6. North Carolina 9.7.1.7. Rest of the U.S. 9.7.2. Canada 9.7.3. Rest of North America 10. EUROPE GLOBAL BACTERIOPHAGE THERAPY MARKET ANALYSIS 10.1. Overview 10.2. Europe Bacteriophage Therapy Historical Market size ($MILLION), Sales Volume, (2022 – 2032) 10.3. Europe Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032) 10.4. Europe Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Application 10.4.1. Food industry 10.4.2. Human Medicine 10.4.3. Veterinary Science 10.4.4. Agriculture 10.4.5. Others 10.5. Europe Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Target Bacteria 10.5.1. E. coli 10.5.2. Staphylococcus aeruginosa 10.5.3. Pseudomonas aeruginosa 10.5.4. Streptococcus 10.5.5. salmonella 10.5.6. Others 10.6. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Route of Administration 10.6.1. Oral 10.6.2. Topical 10.6.3. Rectal 10.6.4. Intravenous 10.7. Europe Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Region 10.7.1. Germany 10.7.2. UK 10.7.3. France 10.7.4. Spain 10.7.5. Italy 10.7.6. Benelux 10.7.7. Rest of Europe 11. ASIA PACIFIC BACTERIOPHAGE THERAPY MARKET ANALYSIS 11.1. Overview 11.2. Asia Pacific Bacteriophage Therapy Historical Market size ($MILLION), Sales Volume, (2022 – 2032) 11.3. Asia Pacific Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032) 11.4. Asia Pacific Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Application 11.4.1. Food industry 11.4.2. Human Medicine 11.4.3. Veterinary Science 11.4.4. Agriculture 11.4.5. Others 11.5. Asia Pacific Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Target Bacteria 11.5.1. E. coli 11.5.2. Staphylococcus aeruginosa 11.5.3. Pseudomonas aeruginosa 11.5.4. Streptococcus 11.5.5. Salmonella 11.5.6. Others 11.6. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Route of Administration 11.6.1. Oral 11.6.2. Topical 11.6.3. Rectal 11.6.4. Intravenous 11.7. Asia Pacific Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Region 11.7.1. China 11.7.2. Japan 11.7.3. Korea 11.7.4. India 11.7.5. Indonesia 11.7.6. Rest of Asia 12. REST OF THE WORLD BACTERIOPHAGE THERAPY MARKET ANALYSIS 12.1. Overview 12.2. Rest of the World Bacteriophage Therapy Market Historical Market size ($MILLION), Sales Volume, (2022 – 2032) 12.3. Rest of the World Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032) 12.4. Rest of the World Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Application 12.4.1. Food industry 12.4.2. Human Medicine 12.4.3. Veterinary Science 12.4.4. Agriculture 12.4.5. Others 12.5. Rest of the World Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Target Bacteria 12.5.1. E. coli 12.5.2. Staphylococcus aeruginosa 12.5.3. Pseudomonas aeruginosa 12.5.4. Streptococcus 12.5.5. Salmonella 12.5.6. Others 12.6. Global Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Route of Administration 12.6.1. Oral 12.6.2. Topical 12.6.3. Rectal 12.6.4. Intravenous 12.7. Rest of the World Bacteriophage Therapy Market size ($MILLION), Sales Volume, and Forecasts (2024 – 2032), By Region 12.7.1. Latin America 12.7.2. Middle East 12.7.3. Africa 13. COMPANY PROFILES 13.1. PHAGOMED BIOPHARMA GMBH 13.1.1. Company Overview 13.1.2. Company Snapshot 13.1.3. Operating business segments 13.1.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.1.5. Key business performances, strategies and developments 13.2. ELIAVA BIOPREPARATIONS LTD 13.2.1. Company Overview 13.2.2. Company Snapshot 13.2.3. Operating business segments 13.2.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.2.5. Key business performances, strategies and developments 13.3. LOCUS BIOSCIENCES 13.3.1. Company Overview 13.3.2. Company Snapshot 13.3.3. Operating business segments 13.3.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.3.5. Key business performances, strategies and developments 13.4. MICREOS BV 13.4.1. Company Overview 13.4.2. Company Snapshot 13.4.3. Operating business segments 13.4.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.4.5. Key business performances, strategies and developments 13.5. NEXTBIOTICS 13.5.1. Company Overview 13.5.2. Company Snapshot 13.5.3. Operating business segments 13.5.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.5.5. Key business performances, strategies and developments 13.6. PHAGELUX 13.6.1. Company Overview 13.6.2. Company Snapshot 13.6.3. Operating business segments 13.6.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.6.5. Key business performances, strategies and developments 13.7. INNOPHAGE 13.7.1. Company Overview 13.7.2. Company Snapshot 13.7.3. Operating business segments 13.7.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.7.5. Key business performances, strategies and developments 13.8. AMRATA PHARMACEUTICALS INC. 13.8.1. Company Overview 13.8.2. Company Snapshot 13.8.3. Operating business segments 13.8.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.8.5. Key business performances, strategies and developments 13.9. TECHNOPHAGE 13.9.1. Company Overview 13.9.2. Company Snapshot 13.9.3. Operating business segments 13.9.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.9.5. Key business performances, strategies and developments 13.10. ADAPTIVE PHAGE THERAPEUTICS 13.10.1. Company Overview 13.10.2. Company Snapshot 13.10.3. Operating business segments 13.10.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.10.5. Key business performances, strategies and developments 13.11. FIXED-PHAGE LTD. 13.11.1. Company Overview 13.11.2. Company Snapshot 13.11.3. Operating business segments 13.11.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.11.5. Key business performances, strategies and developments 13.12. OTHER MARKET PLAYERS 13.12.1. Company Overview 13.12.2. Company Snapshot 13.12.3. Operating business segments 13.12.4. Product Application offered and Revenue from Global Bacteriophage Therapy Business 13.12.5. Key business performances, strategies and developments LIST OF TABLES 1. TABLE: MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 2. TABLE: MARKET FOR FOOD INDUSTRY, BY REGION, 2024-2032 (USD MILLION) 3. TABLE: MARKET FOR HUMAN MEDICINE, BY REGION, 2024-2032 (USD MILLION) 4. TABLE: MARKET FOR VETERINARY SCIENCE, BY REGION, 2024-2032 (USD MILLION) 5. TABLE: MARKET FOR AGRICULTURE, BY REGION, 2024-2032 (USD MILLION) 6. TABLE: MARKET FOR OTHERS, BY REGION, 2024-2032 (USD MILLION) 7. TABLE: MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 8. TABLE: MARKET FOR E. COLI, BY REGION, 2024-2032 (USD MILLION) 9. TABLE: MARKET FOR STAPHYLOCOCCUS AERUGINOSA, BY REGION, 2024-2032 (USD MILLION) 10. TABLE: MARKET FOR PSEUDOMONAS AERUGINOSA, BY REGION, 2024-2032 (USD MILLION) 11. TABLE: MARKET FOR STREPTOCOCCUS, BY REGION, 2024-2032 (USD MILLION) 12. TABLE: MARKET FOR SALMONELLA, BY REGION, 2024-2032 (USD MILLION) 13. TABLE: MARKET FOR OTHERS, BY REGION, 2024-2032 (USD MILLION) 15. TABLE: MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 16. TABLE: MARKET FOR ORAL, BY REGION, 2024-2032 (USD MILLION) 17. TABLE: MARKET FOR TOPICAL, BY REGION, 2024-2032 (USD MILLION) 18. TABLE: MARKET FOR RECTAL, BY REGION, 2024-2032 (USD MILLION) 19. TABLE: MARKET FOR INTRAVENOUS, BY REGION, 2024-2032 (USD MILLION) 20. TABLE: MARKET, BY REGION, 2024-2032 (USD MILLION) 21. TABLE: NORTH AMERICA MARKET, BY REGION, 2024-2032 (USD MILLION) 22. TABLE: NORTH AMERICA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 23. TABLE: NORTH AMERICA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 24. TABLE: NORTH AMERICA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 25. TABLE: USA MARKET BY APPLICATION, 2024-2032 (USD MILLION) 26. TABLE: USA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 27. TABLE: USA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 28. TABLE: CALIFORNIA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 29. TABLE: CALIFORNIA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 30. TABLE: CALIFORNIA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 31. TABLE: TEXAS MARKET BY APPLICATION, 2024-2032 (USD MILLION) 32. TABLE: TEXAS MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 33. TABLE: TEXAS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 34. TABLE: FLORIDA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 35. TABLE: FLORIDA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 36. TABLE: FLORIDA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 37. TABLE: CANADA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 38. TABLE: CANADA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 39. TABLE: CANADA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 40. TABLE: MEXICO MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 41. TABLE: MEXICO MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 42. TABLE: MEXICO MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 43. TABLE: REST OF NORTH AMERICA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 44. TABLE: REST OF NORTH AMERICA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 45. TABLE: NORTH AMERICA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 46. TABLE: EUROPE MARKET, BY REGION, 2024-2032 (USD MILLION) 47. TABLE: EUROPE MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 48. TABLE: EUROPE MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 49. TABLE: EUROPE MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 50. TABLE: UK MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 51. TABLE: UK MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 52. TABLE: UK MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 53. TABLE: SPAIN MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 54. TABLE: SPAIN MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 55. TABLE: SPAIN MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 56. TABLE: BELGIUM MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 57. TABLE: BELGIUM MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 58. TABLE: BELGIUM MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 59. TABLE: SCANDINAVIAN MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 60. TABLE: SCANDINAVIAN MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 61. TABLE: SCANDINAVIAN MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 62. TABLE: GERMANY MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 63. TABLE: GERMANY MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 64. TABLE: GERMANY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 65. TABLE: FRANCE MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 66. TABLE: FRANCE MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 67. TABLE: FRANCE MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 68. TABLE: ITALY MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 69. TABLE: ITALY MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 70. TABLE: ITALY MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 71. TABLE: REST OF EUROPE MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 72. TABLE: REST OF EUROPE MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 73. TABLE: EUROPE MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 74. TABLE: ASIA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 75. TABLE: ASIA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 76. TABLE: ASIA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 77. TABLE: CHINA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 78. TABLE: CHINA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 79. TABLE: CHINA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 80. TABLE: INDIA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 81. TABLE: INDIA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 82. TABLE: INDIA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 83. TABLE: JAPAN MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 84. TABLE: JAPAN MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 85. TABLE: JAPAN MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 86. TABLE: SOUTH KOREA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 87. TABLE: SOUTH KOREA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 88. TABLE: SOUTH KOREA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 89. TABLE: INDONESIA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 90. TABLE: INDONESIA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 91. TABLE: INDONESIA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 92. TABLE: REST OF ASIA MARKET, BY APPLICATION, 2024-2032 (USD MILLION) 93. TABLE: REST OF ASIA MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 94. TABLE: REST OF ASIA MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 95. TABLE: REST OF THE WORLD MARKET, BY APPLICATION,, 2024-2032 (USD MILLION) 96. TABLE: REST OF THE WORLD MARKET, BY TARGET BACTERIA, 2024-2032 (USD MILLION) 97. TABLE: REST OF THE WORLD MARKET, BY ROUTE OF ADMINISTRATION, 2024-2032 (USD MILLION) 98. TABLE: ELIAVA BIOPREPARATIONS LTD: COMPANY SNAPSHOT 99. TABLE: ELIAVA BIOPREPARATIONS LTD: OPERATING SEGMENTS 100. TABLE: LOCUS BIOSCIENCES: COMPANY SNAPSHOT 101. TABLE: LOCUS BIOSCIENCES: OPERATING SEGMENTS 102. TABLE: MICREOS BV: COMPANY SNAPSHOT 103. TABLE: MICREOS BV: OPERATING SEGMENTS 104. TABLE: PHAGOMED BIOPHARMA GMBH COMPANY SNAPSHOT 105. TABLE: PHAGOMED BIOPHARMA GMBH OPERATING SEGMENTS 106. TABLE: NEXTBIOTICS: COMPANY SNAPSHOT 107. TABLE: NEXTBIOTICS: OPERATING SEGMENTS 108. TABLE: PHAGELUX: COMPANY SNAPSHOT 109. TABLE: PHAGELUX: OPERATING SEGMENTS 110. TABLE: INNOPHAGE: COMPANY SNAPSHOT 111. TABLE: INNOPHAGE: OPERATING SEGMENTS 112. TABLE: AMRATA PHARMACEUTICALS INC.: COMPANY SNAPSHOT 113. TABLE: AMRATA PHARMACEUTICALS INC.: OPERATING SEGMENTS 114. TABLE: TECHNOPHAGE: COMPANY SNAPSHOT 115. TABLE: TECHNOPHAGE: OPERATING SEGMENTS 116. TABLE: ADAPTIVE PHAGE THERAPEUTICS: COMPANY SNAPSHOT 117. TABLE: ADAPTIVE PHAGE THERAPEUTICS: OPERATING SEGMENTS LIST OF FIGURES 1. Figure: Market: Research Methodology Steps 2. Figure: Research Design 3. Figure: Breakdown of Primaries: Market 4. Figure: Research Methodology: Hypothesis Building 5. Figure: Market: Product Application and Service-Based Estimation 6. Figure: Top 10 Companies with Highest No. Of Patent in Last 9 Years 7. Figure: Growth Strategies Adopted by the Key Players 8. Figure: No. of Patents Granted Per Year, 2024–2032 9. Figure: Data Triangulation Methodology 10. Figure: Dominating Market Share, By Application, 2024 vs. 2032 (USD MILLION) 11. Figure: Dominating Market Share, By Target Bacteria, 2024 vs. 2032 (USD MILLION) 12. Figure: Dominating Market Share, By Route of Administartion, 2024 vs. 2032 (USD MILLION) 14. Figure: Geographical Snapshot of the Market 15. Figure: Food Industry to Witness Higher Share in the Market for Application Segment during the Forecast Period. 16. Figure: North America Accounted for the Largest Share of the Market, By Regional Basis, in 2024 17. Figure: Market: Drivers, Restraints, Opportunities, and Challenges 18. Figure: Asia: Market Snapshot 19. Figure: Europe: Market Snapshot 20. Figure: Middle East: Market Snapshot 21. Figure: Vendor Dive: Evaluation Overview 22. Figure: Bacteriophage Therapy: Competitive Benchmarking 23. Figure: Eliava Biopreparations Ltd: Financial Overview (2024-2032) 24. Figure: Locus Biosciences: Financial Overview (2024-2032) 25. Figure: PHAGOMED BIOPHARMA GMBH Financial Overview (2024-2032) 26. Figure: Nextbiotics: Financial Overview (2024-2032) 27. Figure: Phagelux: Financial Overview (2024-2032) 28. Figure: Amrata Pharmaceuticals Inc.: Financial Overview (2024-2032) 29. Figure: TechnoPhage: Financial Overview (2024-2032) 30. Figure: Adaptive Phage Therapeutics: Financial Overview (2024-2032)